miR-145 Alleviates Smooth Muscle Cell Phenotype Transition via ADAM17-Mediated ACE2 Shedding

Figure 3

miR-145 modulates contractile and synthetic phenotype after Ang II treatment in vitro. VSMCs were treated with miR-145 mimic (100 nM) or miR-145 inhibitor (100 nM) in the presence or absence of Ang II (1 μM) for 48 hours. (a–e) Protein expression of α-SMA, SM22α, OPN, EREG, and MMP2 from panel (f) and the data were normalized to that of GAPDH. vs. control group; vs. control group; ^## vs. Ang II group; and ^# vs. Ang II group. All the data are expressed as mean ± SEM from three independent experiments. miRNA NC, negative control miRNA.

(a)

(b)

(c)

(d)

(e)

(f)